References
Ahuja SS, Reddick RL, Sato N, Montalbo E, Kostecki V, Zhao W, Dolan MJ, Melby PC, Ahuja SK (1999) Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. J Immunol l63:3890–3897
Araujo Z, Heremans H, Stordeur P, Wissing M, Goldman M, Castes M, Carlier Y (2000) IFN-gamma, IL-4, IL-10 and IL-12 gene expression in BCG-Leishmania vaccination of Trypanosoma cruzi-infected mice. Vaccine 18:1822–1829
Bancroft AJ, McKenzie ANJ, Grencis RK (1998) A critical role for IL-13 in resistance to intestinal nematode infection. J Immunol 160:3453–3461
Bancroft AJ, Artis D, Donaldson DD, Sypek JP, Grencis RK (2000) Gastrointestinal nematode expulsion in IL-4 knockout mice is IL-13 dependent. Eur J Immunol 30:2083–2091
Barral-Neto MA, Barral CE, Browne ll, Skeiky YAW, Ellingworth LR, Twardzik DR, Reed SG (1992) Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science 257:545–548
Barreto ML, Rodrigues LC, Silva RC, Assis AM, Reis MG, Santos CA, Blanton RE (2000) Lower hookworm incidence, prevalence, and intensity of infection in children with a Bacillus Calmette-Guerin vaccination scar. J Infect Dis 182:1800–1803
Bermudez LE, Covaro G, Remington J (1993) Infection of murine macrophages with Toxoplasma gondii is associated with release of transforming growth factor beta and downregulation of expression of tumor necrosis factor receptors. Infect Immun 61:4126–4130
Bliss SK, Butcher BA, Denkers EY (2000) Rapid recruitment of neutrophils containing prestored IL-12 during microbial infection. J Immunol 165:4515–4521
Bourreau E, Prevot G, Pradinaud R, Launois P (2001) Unresponsiveness of specific T cells to IL-12 is associated with active cutaneous leishmaniasis owing to Leishmania guyanensis. Scand J Immunol 54:335–339
Buates S, Matlashewski G (1999) Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J Infect Dis 179:1485–1494
Bungiro RD Jr, Goldberg M, Suri PK, Knopf PM (1999) Interleukin-12 as an adjuvant for an antischistosome vaccine consisting of adult worm antigens: protection of rats from cercarial challenge. Infect Immun 67:2340–2348
Chao CC, Hu S, Gekker G, Novick WJ, Remington JS, Peterson PK(1993) Effects of cytokines on multiplication of Toxoplasma gondii in microglial cells. J Immunol 150:3403–3410
Chen G, Darrah PA, Mosser DM (2001) Vaccination against the intracellular pathogens Leishmania major and L. amazonensis by directing CD40 ligand to macrophages. Infect Immun 69:3255–3263
Chiaramonte MG, Hesse M, Cheever AW, Wynn TA (2000) CpG oligonucleotides can prophylactically immunize against Th2-mediated schistosome egg-induced pathology by an IL-12-independent mechanism. J Immunol 164:973–985
Corral RS, Petray PB (2000) CpG DNA as aTh1-promoting adjuvant immunization against Trypanosoma cruzi. Vaccine 19:234–242
Doherty TM, Coffman RL (1999) Ability of macrophage subsets to transfer resistance to murine leishmaniasis is dependent on IL-12 production. Eur Immunol 29:522–529
Dvoroznakova E, Boroskova Z, Dubinsky P, Tomasovicova O, Hribalova V, Machnicka B (1999) Immunomodulative effect of muramyldipeptide in mice with larval toxocarosis. Parasitol Res 85:1034–1040
Eslami Z, Gaucher D, Tanner CE (1996) Synergism of IL-2-stimulated splenocytes and Pentostam enhances the killing of Leishmania donovani in vitro. Clin Immunol Immunopathol 81:74–81
Fallon PG, Richardson EJ, McKenzie GJ, McKenzie AN (2000) Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. J Immunol 164:2585–2591
Fernandes AP, Carvalho FA, Tavares CA, Santiago HC, Castro GA, Tafuri WL, Ferreira LA, Gazzinelli RT (2001) Combined interleukin-12 and topical chemotherapy for established Leishmanias drastically reduces tissue parasitism and relapses in susceptible mice. J Infect Dis 183:1646–1652
Finkelman FD, Wynn TA, Donaldson DD, Urban JF (1999) The role of IL-13 in helminth-induced inflammation and protective immunity against nematode infections. Curr Opin Immunol 11:420–426
Follador I, Araujo C, Orge G, Cheng LH, Carvalho LP de, Bacellar O, Almeida RP, Carvalho EM (2002) Immune responses to an inactive vaccine against American cutaneous leishmaniasis together with granulocyte–macrophage colony-stimulating factor. Vaccine 20:1365–1368
Gabaglia CR, Pedersen B, Hitt M, Burdin N, Sercarz EE, Graham FL, Gauldie J, Braciak TA (1999) A single intramuscular injection with an adenovirus-expressing IL-12 protects BALB/c mice against Leishmania major infection, while treatment with an IL-4 expressing vector increases disease susceptibility in B10.D2 mice. J Immunol 162:753–760
Heinze FP, Schoenhaut DM, Rerko RM, Rosser LE, Gately MK(1993) Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 177:1505–1509
Jones DE, Buxbaum LU, Scott P (2000) IL-4-independent inhibition of IL-12 responsiveness during Leishmania amazonensis infection. J Immunol 165:364–372
Kenney RT, Sacks DL, Sypek JP, Vilela L, Garn AA, Evans-Davis K (1999) Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol 163:4481–4488
Khan IA, Casciotti L (1999) IL-15 prolongs the duration of CD8+ T cell-mediated immunity in mice infected with a vaccine strain of Toxoplasma gondii. J Immunol 163:4503–4509
Kole L, Das L, Das PK(1999) Synergistic effect of interferon-gamma and mannosylated liposome-incorporated doxorubicin in the therapy of experimental visceral leishmaniasis. J Infect Dis 180:811–820
Kremer IB, Gould MP, Cooper KD, Heinzel FP (2001) Pretreatment with recombinant F1t3 ligand partially protects against progressive cutaneous leishmaniasis in susceptible BALB/c mice. Infect Immun 69:673–680
Lehmann J, Enssle KH, Lehmann I, Emmendorfer A, Lohmann-Matthes ML (2000) The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice. J Interferon Cytokine Res 20:63–77
Li J, Hunter CA, Farrell JP (1999) Anti-TGF-beta treatment promotes rapid healing of Leishmania major infection in mice by enhancing in vivo nitric oxide production. J Immunol 162:974–979
Luty AJ, Perkins DJ, Lell B, Schmidt-Ott R, Lehman LG, Luckner D, Greve B, Matousek P, Herbich K, Schmid D, Weinberg JB, Kremsner PG (2000) Low interleukin-12 activity in severe Plasmodium falciparum malaria. Infect Immun 68:3909–3915
Masihi KN (1994) Immunotherapy of infections. Dekker, New York
Masihi KN (2000) Immunomodulators in infectious diseases: panoply of possibilities. Int J Immunopharmacol 22:1083–1091
Masihi KN (2001) Fighting infection using immunomodulatory agents. Expert Opin Biol Ther 1:641–653
Matsumoto S, Yukitake H, Kanbara H, Yarnada H, Kitamura A, Yamada T (2000) Mycobacterium bovis bacillus Calmette–Guerin induces protective immunity against infection by Plasmosdium yoelii at blood-stage depending on shifting immunity toward Th1 type and inducing protective IgG2a after the parasite infection. Vaccine 19:779–787
Matthews DJ, Emson CL, McKenzie GJ, Jolin HE, Blackwell JM, McKenzie AN (2000) IL13 is a susceptibility factor for Leishmania major infection. J Immunol 164:1458–1462
McDowell MA, Sacks DL (1999) Inhibition of host cell signal transduction by Leishmania: observations relevant to the selective impairment of IL-12 responses. Curr Opin Microbiol 2:438–443
McKenzie GJ, Bancroft A, Grencis RK, McKenzie AN (1998) A distinct role for interleukin-13 in Th2 cell-mediated immune responses. Curr Biol 8:339–342
Mohan K, Sam H, Stevenson MM (1999) Therapy with a combination of low doses of interleukin 12 and chloroquine completely cures blood-stage malaria, prevents severe anemia, and induces immunity to reinfection. Infect Immun 67:513–519
Murray HW, Montelibano C, Peterson R, Sypek JP (2000) Interleukin-12 regulates the response to chemotherapy in experimental visceral leishmaniasis. J Infect Dis 182:1497–1502
Nickdel MB, Roberts F, Brombacher F, Alexander J, Roberts CW (2001) Counter-protective role for interleukin-5 during acute Toxoplasma gondii infection. Infect Immun 69:1044–1052
Perez-Santos JL, Talamas-Rohana P (2001) In vitro indomethacin administration upregulates interleukin-12 production and polarizes the immune response towards a Th1 type in susceptible BALB/c mice infected with Leishmania mexicana. Parasite Immunol 23:599–606
Quinones M, Ahuja SK, Melby PC, Pate L, Reddick RL, Ahuja SS (2000) Preformed membrane-associated stores of interleukin (IL)-12 are a previously unrecognized source of bioactive IL-12 that is mobilized within minutes of contact with an intracellular parasite. J Exp Med 192:507–516
Reichmann G, Walker W, Villegas EN, Craig L, Cai G, Alexander J, Hunter CA (2000) The CD40/CD40 ligand interaction is required for resistance to toxoplasmic encephalitis. Infect Immun 68:1312–1318
Rivier D, Bovay P, Shah R, Didisheim S, Mauel J (1999) Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection. Parasite Immunol 21:461–473
Saha B, Saini A, Germond R, Perrin PJ, Harlan DM, Davis TA (1999) Susceptibility or resistance to Leishmania infection is dictated by the macrophages evolved under the influence of IL-3 or GM-CSF. Eur J Immunol 29:2319–2329
Sakai T, Hisaeda H, Nakano Y, Ishikawa H, Maekawa Y, Ishii K, Nitta Y, Miyazaki J, Himeno K (2000) Gene gun-mediated delivery of an interleukin-12 expression plasmid protects against infections with the intracellular protozoan parasites Leishmania major and Trypanosoma cruzi in mice. Immunology 99:615–624
Satoskar AR, Rodig S, Telford SR, Satoskar AA, Ghosh SK, Lichtenberg F von, David JR (2000) IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology. Eur J Immunol 30:834–839
Sauder DN (2000) Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 43:S6–S11
Silva JS, Twrdzik DR, Reed SG (1991) Regulation of Trypanosoma cruzi infections in vitro and in vivo by transforming growth factor beta (TGF-beta). J Exp Med 174:539–545
Stacey KJ, Blackwell JM (1999) Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect Immun 67:3719–3726
Stamm LM, Satoskar AA, Ghosh SK, David JR, Satoskar AR (1999) STAT-4 mediated IL-12 signaling pathway is critical for the development of protective immunity in cutaneous leishmaniasis. Eur J Immunol 29:2524–2529
Stevenson MM, Su Z, Sam H, Mohan K (2001) Modulation of host responses to blood-stage malaria by interleukin-12: from therapy to adjuvant activity. Microbes Infect 2001:49–59
Walker PS, Scharton-Kersten T, Krieg AM, Love-Homan L, Rowton ED, Udey MC, Vogel JC (1999) Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc Natl Acad Sci USA 96:6970–6975
Yamakami K, Akao S, Sato M, Nitta Y, Miyazaki J, Tadakuma T (2001) A single intradermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection. Parasitol Int 50:81–91
Yap G, Pesin M, Sher A (2000) Cutting edge: IL-12 is required for the maintenance of IFN-gamma production in T cells mediating chronic resistance to the intracellular pathogen, Toxoplasma gondii. J Immunol 165:628–631
Zhang Y, Denkers EY (1999) Protective role for interleukin-5 during chronic Toxoplasma gondii infection. Infect Immun 67:4383–4392
Zimmermann S, Egeter O, Hausmann S, Lipford GB, Rocken M, Wagner H, Heeg K (1998) CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol 160:3627–3630
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Masihi, K.N. Concepts of immunostimulation to increase antiparasitic drug action. Parasitol Res 90 (Suppl 2), S97–S104 (2003). https://doi.org/10.1007/s00436-002-0774-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00436-002-0774-5